Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lemaitre Vascular (NQ: LMAT )

55.47 -1.53 (-2.68%)
Streaming Delayed Price Updated: 1:15 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lemaitre Vascular

< Previous 1 2 3 Next >
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Looking for Dividend Growth? Buy This Little-Known Healthcare Stock
The healthcare company's dividend has soared in recent years. 
Via The Motley Fool
Recap: LeMaitre Vascular Q1 Earnings
Via Benzinga
Buy This Under-the-Radar Stock for Dividend Growth
This specialty medical device maker treats its shareholders well. 
Via The Motley Fool
Is This Small-Cap Dividend Stock a Buy?
LeMaitre Vascular isn't well-known to investors. But vascular surgeons do know the company well. 
Via The Motley Fool
2 Healthcare Stocks That Could Help Make You a Fortune
These companies did well for shareholders over the last 10 years and have the potential to keep the growth going. 
Via The Motley Fool
Boston Scientific Stock Gets 81 RS Rating After Profit Pops 56% In Year
Boston Scientific stock rose from a 34.98 low on June 16, 2022, amid the bear market, to an all-time high 54.66 close on June 22 this year. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
Is This Underfollowed Dividend Stock a Buy?
The medical device maker flies under the radar of most investors. 
Via The Motley Fool
Yum! Brands To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Thursday
Needham raised the price target for Extreme Networks, Inc. (NASDAQ: EXTR) from $30 to $35. Needham analyst Alex Henderson maintained a Buy rating. Extreme Networks shares fell 1.7% to $29.70 in... 
Via Benzinga
3 Micro-Cap Stocks to Buy Now for Gigantic Growth Potential
The smallest stocks have been trailing their larger counterparts. Here are three top micro-cap stocks to ride the asset class' resurgence. 
Via InvestorPlace
Beat the Dow Jones With This Unstoppable Dividend Stock
The wealth created by this medical devices company for its investors over the past decade far exceeds what the Dow Jones generated. 
Via The Motley Fool
Is This Healthcare Stock a Buy for Dividend Growth Investors?
This medical device maker has crushed the S&P 500 index in the past 10 years. 
Via The Motley Fool
Why Shares of LeMaitre Vascular Are Up Wednesday
LeMaitre announced first-quarter earnings and guidance numbers. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
Via Benzinga
The Best Dividend Achievers
The Dividend Achievers show a minimum of 10 consecutive years with a dividend increase. Here are some of the top Dividend Achievers from 5 different sectors. 
Via Talk Markets
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time for a dive into the latest stock market happenings with the biggest pre-market stock movers worth watching on Friday! 
Via InvestorPlace
Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years
These two stocks have generated massive dividend growth for shareholders in the last decade. 
Via The Motley Fool
Weibo, XPeng, Li Auto And Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Stocks Boast Midday Gains On Road To Big Weekly Weekly Wins
Wall Street is brushing off a dismal earnings report from Amazon.com, and opting to favor unsurprising inflation and steady consumer spending data. 
Via Talk Markets
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
Upgrades 
Via Benzinga
Why Edwards Lifesciences Shares Are Trading Lower By Around 17%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) surged 179% to $3.6301. 
Via Benzinga
High Growth Potential Small-Cap Dividend Stock Ideas [Podcast]
Looking for growth in the dividend world? Small caps are in for a rollercoaster ride, but can bring a lot of growth to your portfolio. Often overlooked, these companies still tend to outperform large... 
Via Talk Markets
Recap: LeMaitre Vascular Q4 Earnings
LeMaitre Vascular (NASDAQ:LMAT) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.